[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TW200833340A - Imidazo [1, 2-b] pyridazine derivatives - Google Patents

Imidazo [1, 2-b] pyridazine derivatives

Info

Publication number
TW200833340A
TW200833340A TW096147803A TW96147803A TW200833340A TW 200833340 A TW200833340 A TW 200833340A TW 096147803 A TW096147803 A TW 096147803A TW 96147803 A TW96147803 A TW 96147803A TW 200833340 A TW200833340 A TW 200833340A
Authority
TW
Taiwan
Prior art keywords
alkyl group
hydrogen atom
compound
solvate
tnf
Prior art date
Application number
TW096147803A
Other languages
Chinese (zh)
Inventor
Takanori Yasukouchi
Shin Iimura
Yoshiyuki Yoneda
Hiroki Shimizu
Tomonori Yamasaki
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of TW200833340A publication Critical patent/TW200833340A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provide a novel low molecular compound with TNF-α production inhibiting action, by which an excellent effect in an inflammatory disease and / or an autoimmune disease condition model is demonstrated, and also offers high safety and the oral administration possibility. The present invention relates to a compound of the following formula(I) [wherein R1 represents a hydrogen atom or a C1-C6 alkyl alkyl group R2 represents an optionally substituted C1-C6 alkyl group, Ring A represents a benzene ring etc., X represents a hydrogen atom or the same or different 1 to 3 groups selected from a group cosisting of a halogen atom and a C1-C6 alkyl group etc., Y represent a group of the following formula: N(R3a)C(R6aR7a)C(R8aR9a)N(R4aR5a)etc. (wherein, each of R3a, R4a, R5a, R6a, R7a, R8a, R9a may be the same or different, indendently represents a hydrogen atom or a C1-C6 alkyl group etc.], or its salt or solvate thereof, and also relates to a TNF-α production inhibitor consisting of the compound or its salt or solvate thereof as an active ingredient.
TW096147803A 2006-12-15 2007-12-14 Imidazo [1, 2-b] pyridazine derivatives TW200833340A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006337703 2006-12-15

Publications (1)

Publication Number Publication Date
TW200833340A true TW200833340A (en) 2008-08-16

Family

ID=39511698

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096147803A TW200833340A (en) 2006-12-15 2007-12-14 Imidazo [1, 2-b] pyridazine derivatives

Country Status (2)

Country Link
TW (1) TW200833340A (en)
WO (1) WO2008072682A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200918065A (en) * 2007-09-28 2009-05-01 Daiichi Sankyo Co Ltd Imidazopyridazine derivatives
EP2710004A1 (en) 2011-05-17 2014-03-26 Bayer Intellectual Property GmbH Amino-substituted imidazopyridazines as mknk1 kinase inhibitors
ES2625854T3 (en) 2011-06-01 2017-07-20 Bayer Intellectual Property Gmbh Aminoimidazopyridazines substituted
CN103764656A (en) 2011-06-22 2014-04-30 拜耳知识产权有限责任公司 Heterocyclyl aminoimidazopyridazines
UA117092C2 (en) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Amino-substituted imidazopyridazines
EP2758400A1 (en) 2011-09-23 2014-07-30 Bayer Intellectual Property GmbH Substituted imidazopyridazines
US9643974B2 (en) 2011-12-12 2017-05-09 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
WO2013144189A1 (en) 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Amino-substituted imidazopyridazines
US9409889B2 (en) 2012-04-04 2016-08-09 Bayer Pharma Aktiengesellschaft Amino-substituted imidazopyridazines
TWI585088B (en) * 2012-06-04 2017-06-01 第一三共股份有限公司 Imidazo[1,2-b]pyridazine analogues as kinase inhibitors
PT2925757T (en) 2012-11-19 2018-01-09 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
CN104797585B (en) 2012-11-19 2017-08-15 拜耳医药股份公司 Aminoimidazopyridazines
CA2899352A1 (en) 2013-01-30 2014-08-07 Bayer Pharma Aktiengesellschaft Amidoimidazopyridazines as mknk-1 kinase inhibitors
CA2901527A1 (en) 2013-02-20 2014-08-28 Bayer Pharma Aktiengesellschaft Substituted-imidazo[1,2-b]pyridazines as mknk1 inhibitors
US9370515B2 (en) 2013-03-07 2016-06-21 Califia Bio, Inc. Mixed lineage kinase inhibitors and method of treatments
GB201321734D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
ES2702126T3 (en) 2013-12-10 2019-02-27 Bristol Myers Squibb Co Imidazopyridazine compounds useful as modulators of responses to IL-12, IL-23 and / or IFN alpha
CN105899512A (en) 2014-01-09 2016-08-24 拜耳医药股份公司 Amide group substituted imidazopyridazines useful in the treatment of hyperproliferative and/or angiogenic diseases
KR102696304B1 (en) * 2015-03-18 2024-08-16 브리스톨-마이어스 스큅 컴퍼니 Heterocyclic compounds useful as inhibitors of TNF

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0017543D0 (en) * 2000-07-17 2000-09-06 Merck Sharp & Dohme Therapeutic agents
GB0223349D0 (en) * 2002-10-08 2002-11-13 Merck Sharp & Dohme Therapeutic agents
NZ548098A (en) * 2003-12-31 2010-05-28 Schering Plough Ltd Control of parasites in animals by the use of imidazo[1,2-b]pyridazine derivatives

Also Published As

Publication number Publication date
WO2008072682A1 (en) 2008-06-19

Similar Documents

Publication Publication Date Title
TW200833340A (en) Imidazo [1, 2-b] pyridazine derivatives
TW200642683A (en) Heterocyclic compound
MY136643A (en) Pyrimidine derivatives for inhibition of cell-proliferation
TW200738241A (en) Pyridazine derivatives
EP1679309A4 (en) Antistress drug and medical use thereof
YU69902A (en) New piperazine derivatives
HUP0300148A2 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
EP1248612A4 (en) Novel compounds and compositions as protease inhibitors
ECSP067111A (en) DERIVATIVES OF PIRIDO-PIRIMIDINA, ITS PREPARATION, ITS APPLICATION IN THERAPEUTICS
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
TW200635930A (en) Bicyclic pyrrole derivatives
EP1361220A4 (en) Cyclic compounds having thrombopoietin receptor agonism
TW200626558A (en) Indazolone derivatives
RS101304A (en) indole,azaindole and related heterocyclic 4-alkenyl piperadine amides
GEP20156267B (en) 1H-IMIDAZO[4,5-c]QUINOLINONE DERIVATIVES
EP1340755A4 (en) Anti-helicobacterial agents
HUP0400246A2 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
MY145464A (en) Pyrazolone derivatives as 11-beta hsd1 inhibitors
YU56302A (en) 8,8a-dihydro-indeno/1,2-d/thiazol-derivatives, substituted in position 8a, a method for their production and their use as medicaments, e.g.anorectic agents
PL1682528T3 (en) BENZO [b][1,4] DIOXEPINE DERIVATIVES
TW200621759A (en) Novel aminopyridine derivatives having aurora A selective inhibitory action
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
MX2009003169A (en) Sulfonamide derivatives.